Trending News

Cancer cell
#Biomarkers #Breast cancer #Cancer research #Genetics / genomics #Oncology #Personalised medicine #The Institute of Cancer Research

Genetic biomarkers could personalise therapy for TNBC

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours… Read More

#Cancer Research #News #Trending News

Human neurone
#Artificial intelligence (AI) #Francis Crick Institute #Neurodegenerative disorders #Neurology #Parkinson's #Personalised medicine

AI Parkinson’s discovery paves way for personalised treatments

A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology… Read More

#News #Trending News

Warfarin
#Cancer research #Columbia University #Drug repurposing #Oncology

Warfarin could be repurposed as a potent cancer drug

A new study has shown that blood thinner warfarin could also treat cancer, as it stops tumours from interfering with a self-destruct mechanism that cells initiate when they detect mutations or other abnormalities (ferroptosis). The research by Columbia University researchers was conducted in human cells and… Read More

#Cancer Research #News #Trending News

Covid-19
#Antivirals #Covid-19 #Covid-19 treatment #Infex Therapeutics #Preclinical investigations

New antiviral potential solution to resistant Covid-19 variants

In preclinical studies, a new pan-coronavirus papain-like protease (PLpro) inhibitor has shown a near complete reduction in SARS-CoV-2 viral load in the lungs. Infex Therapeutics has selected the clinical candidate for its in-house COV-X programme based on this in vivoefficacy data in a murine SARS-CoV-2 model. Read More

#News #Trending News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

Haemophilia
#CSL #Gene therapy #Haemophilia #National Institute for Health and Care Excellence (NICE)

UK health watchdog rejects gene therapy for haemophilia B

In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted a marketing authorisation by the UK Medicines… Read More

#News #Regulatory #Trending News

#Cancer drug targets #Cancer research #Cancer vaccine #Immunotherapy #Lung cancer #Oncology

World Lung Cancer Day: Five drug discovery breakthroughs

This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More

#Cancer Research #News #Trending News

Biogen head office
#ALS #Alzheimer's #Biogen #Business #Investment #Mergers and acquisitions

Biogen acquires Reata and cuts 1,000 jobs

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said… Read More

#Business & Investment #News #Trending News

Human eye
#Cell and gene therapy #Gene therapy #Krystal Biotech #Ophthalmology

First-of-its-kind gene therapy restores vision in DEB patient

A dystrophic epidermolysis bullosa (DEB) patient at the Bascom Palmer Eye Institute, University of Miami, US, has regained his vision after being the first person to receive a formulation of gene therapy Vyjuvek suitable for the eyes. DEB is a rare genetic condition that makes the… Read More

#News #Trending News

Click chemistry
#Cancer research #Click chemistry #Immunotherapy #Oncology #Stanford University #University College London

Novel anti-cancer therapy created using click chemistry

A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More

#Cancer Research #News #Trending News

Scientific papers
#Academic #Data management #Neuroscience #Stanford University

Stanford president quits following false data accusations

The president of Stanford University in the US has announced he will resign after the university found that scientific papers he had published contained manipulated research data. The scientific misconduct inquiry did not find neuroscientist Marc Tessier-Lavigne guilty of falsifying research personally, but said that papers… Read More

#News #Trending News

Alzheimer's disease
#Alzheimer's #Clinical trials #Eli Lilly #Neuroscience

Donanemab significantly slowed decline in early Alzheimer’s disease trial 

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More

#News #Trending News

Long Covid
#Chronic Fatigue Syndrome #Covid-19 #Genetic profiling #Genetics / genomics #Long Covid

Ground-breaking study identifies novel drug targets for long Covid

A study into long Covid has provided the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Despite considerable global research, studies have so far failed to identify the detailed genetic risk factors for long Covid,… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Oncology #Phase II trial

A third of clinical trials cancelled during Phase II

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. Read More

#News #Trending News

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News

Woman uses Digital Glucose meter
#allogeneic cell therapies #Cell and gene therapy #Diabetes #FDA #Type 1 diabetes

FDA approves first cellular therapy for type 1 diabetes

The US Food and Drug Administration has approved CellTrans’ Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable… Read More

#News #Trending News